Utama › Kanser Paru-paru › Michigan › Flint
Kajian klinikal Kanser Paru-paru di Flint, MI
10 kajian untuk Kanser Paru-paru sedang mencari peserta di lokasi dalam dan sekitar Flint (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Mengambil pesertaFasa 3
- Cancer Hematology Centers - Flint, Flint
- Genesys Hurley Cancer Institute, Flint
- Hurley Medical Center, Flint
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Cancer Hematology Centers - Flint, Flint
- Genesee Hematology Oncology PC, Flint
- Genesys Hurley Cancer Institute, Flint
- dan 1 lagi
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Mengambil pesertaFasa 3
- Cancer Hematology Centers - Flint, Flint
- Genesys Hurley Cancer Institute, Flint
- Hurley Medical Center, Flint
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Mengambil pesertaFasa 3
- Cancer Hematology Centers - Flint, Flint
- Genesys Hurley Cancer Institute, Flint
- Hurley Medical Center, Flint
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Mengambil pesertaFasa 3
- Cancer Hematology Centers - Flint, Flint
- Genesys Hurley Cancer Institute, Flint
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Mengambil pesertaFasa 3
- McLaren Cancer Institute-Flint, Flint
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Mengambil pesertaFasa 3
- McLaren Cancer Institute-Flint, Flint
- McLaren Cancer Institute-Lapeer Region, Lapeer · 19 mi jauh
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2
- Cancer Hematology Centers - Flint, Flint
- Genesys Hurley Cancer Institute, Flint
- Hurley Medical Center, Flint
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2
- Cancer Hematology Centers - Flint, Flint
- Genesys Hurley Cancer Institute, Flint
- Hurley Medical Center, Flint
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2/3
- Cancer Hematology Centers - Flint, Flint
- Genesys Hurley Cancer Institute, Flint
Kajian Kanser Paru-paru di bandar lain
- Houston, TX78 kajian
- Boston, MA62 kajian
- New York City, NY60 kajian
- Los Angeles, CA45 kajian
- Washington, DC41 kajian
- Arlington, VA41 kajian
- Chicago, IL41 kajian
- Nashville, TN40 kajian
- Baltimore, MD40 kajian
- St. Louis, MO39 kajian
- Columbus, OH37 kajian
- Philadelphia, PA36 kajian
Kajian lain di Flint
- Kanser Paru-paru Bukan Sel Kecil9 kajian
- Kanser Payudara9 kajian
- Kanser Prostat7 kajian
- Kanser Kolorektal6 kajian
- Leukemia Mieloid Akut6 kajian
- Kanser (semua jenis)5 kajian
- Lupus4 kajian
- Karsinoma Sel Skuamosa Kepala dan Leher4 kajian
- Kanser Hipofaring4 kajian
- Kanser Laring4 kajian
- Kanser Oral4 kajian
- Kanser Ginjal (Karsinoma Sel Renal)3 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.